Aflibercept (Zaltrap) is a VEGF-A/VEGF-B inhibitor that binds to VEGF and acts as a “VEGF trap,” inhibiting the growth of new blood vessels in metastatic CRC [73]. This evidence concerns the gene VEGFA and colorectal carcinoma.